Jiangsu Osaikang injection with Grebenzene was approved clinically.

Guided reading: Injection with glibenzene is a selective sulfonate-like inhibitor 1 (SUR1).
. On September 7, Beijing Osaikang Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Jiangsu Osaikang Pharmaceutical Co., Ltd., had recently received a notice of approval for clinical trials of injectable grebenzene issued by the State Drug AdministrationChinese.
Injection Grebenzene is a class 2 new drug jointly developed by Jiangsu Osaikang Pharmaceutical Co., Ltd. and the Military Medical Research Institute of the Chinese People's Liberation Army Academy of Military Sciences with independent intellectual property rights; 1 (SUR1) inhibitors, by blocking the SUR1-TRPM4 (instantaneously subject potential M4) channel to play a neuropulative role;
(acute spinal cord injury, acute brain trauma, ischemic stroke) is the leading cause of death and long-term disability.
At present, acute CNS injury has a high incidence rate, critical illness, complex treatment, with rapid deterioration of the disease, late complications, high mortality characteristics, some patients have sequelae, including permanent loss of sensory function, limb movement function, reproductive function, detox function, etc., to patients and their families, and even society to bring a heavy burden, is a serious public health problem.
post-traumatic nerve cell edema causes the patient's vital signs to deteriorate, neurofunctic deficiency, is one of the current medical problems.
in this field, there is still a lack of effective therapeutic drugs, there is a great clinical demand, the market potential is large.
Jiangsu Osaikang Pharmaceutical Co., Ltd. completed the pharmaceutical research, pharmacological toxicology research and clinical trial program design of Glibenzia injection, submitted a clinical trial application (IND) to the Drug Administration and obtained clinical trial approval.
products at home and abroad have not been approved for listing.
.